Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05064358 · BASELINE

Baseline characteristics

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma · Source last updated 2026-05-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      40
    2. group Id
      BG001
      value
      40
    3. group Id
      BG002
      value
      40
    4. group Id
      BG003
      value
      40
    5. group Id
      BG004
      value
      17
    6. group Id
      BG005
      value
      177
    units
    Participants
groups
  1. description
    Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG000
    title
    Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)
  2. description
    Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG001
    title
    Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W
  3. description
    Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG002
    title
    Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)
  4. description
    Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG003
    title
    Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W
  5. description
    Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death. For this arm, dose modification decisions were determined by the results of the Ocular Surface Disease Index (OSDI) questionnaire or VA assessments using Snellen chart. The OSDI scale assesses the severity of eye symptoms and their impact and Snellen chart is for the assessment of visual acuity.
    id
    BG004
    title
    Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
  6. description
    Total of all reporting groups
    id
    BG005
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.36
          value
          66.6
        2. group Id
          BG001
          spread
          9.02
          value
          63.0
        3. group Id
          BG002
          spread
          9.92
          value
          63.7
        4. group Id
          BG003
          spread
          8.87
          value
          65.4
        5. group Id
          BG004
          spread
          10.42
          value
          67.1
        6. group Id
          BG005
          spread
          9.66
          value
          64.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    YEARS
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          19
        2. group Id
          BG001
          value
          21
        3. group Id
          BG002
          value
          19
        4. group Id
          BG003
          value
          16
        5. group Id
          BG004
          value
          8
        6. group Id
          BG005
          value
          83
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          21
        2. group Id
          BG001
          value
          19
        3. group Id
          BG002
          value
          21
        4. group Id
          BG003
          value
          24
        5. group Id
          BG004
          value
          9
        6. group Id
          BG005
          value
          94
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          13
        2. group Id
          BG001
          value
          9
        3. group Id
          BG002
          value
          12
        4. group Id
          BG003
          value
          6
        5. group Id
          BG004
          value
          6
        6. group Id
          BG005
          value
          46
      title
      Hispanic or Latino
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          27
        2. group Id
          BG001
          value
          31
        3. group Id
          BG002
          value
          28
        4. group Id
          BG003
          value
          34
        5. group Id
          BG004
          value
          11
        6. group Id
          BG005
          value
          131
      title
      Not Hispanic or Latino
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      40
    2. group Id
      BG001
      value
      40
    3. group Id
      BG002
      value
      40
    4. group Id
      BG003
      value
      40
    5. group Id
      BG004
      value
      17
    6. group Id
      BG005
      value
      177
    units
    Participants
groups
  1. description
    Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG000
    title
    Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)
  2. description
    Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG001
    title
    Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W
  3. description
    Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG002
    title
    Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)
  4. description
    Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.
    id
    BG003
    title
    Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W
  5. description
    Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death. For this arm, dose modification decisions were determined by the results of the Ocular Surface Disease Index (OSDI) questionnaire or VA assessments using Snellen chart. The OSDI scale assesses the severity of eye symptoms and their impact and Snellen chart is for the assessment of visual acuity.
    id
    BG004
    title
    Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)
  6. description
    Total of all reporting groups
    id
    BG005
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.36
          value
          66.6
        2. group Id
          BG001
          spread
          9.02
          value
          63.0
        3. group Id
          BG002
          spread
          9.92
          value
          63.7
        4. group Id
          BG003
          spread
          8.87
          value
          65.4
        5. group Id
          BG004
          spread
          10.42
          value
          67.1
        6. group Id
          BG005
          spread
          9.66
          value
          64.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    YEARS
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          19
        2. group Id
          BG001
          value
          21
        3. group Id
          BG002
          value
          19
        4. group Id
          BG003
          value
          16
        5. group Id
          BG004
          value
          8
        6. group Id
          BG005
          value
          83
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          21
        2. group Id
          BG001
          value
          19
        3. group Id
          BG002
          value
          21
        4. group Id
          BG003
          value
          24
        5. group Id
          BG004
          value
          9
        6. group Id
          BG005
          value
          94
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          13
        2. group Id
          BG001
          value
          9
        3. group Id
          BG002
          value
          12
        4. group Id
          BG003
          value
          6
        5. group Id
          BG004
          value
          6
        6. group Id
          BG005
          value
          46
      title
      Hispanic or Latino
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          27
        2. group Id
          BG001
          value
          31
        3. group Id
          BG002
          value
          28
        4. group Id
          BG003
          value
          34
        5. group Id
          BG004
          value
          11
        6. group Id
          BG005
          value
          131
      title
      Not Hispanic or Latino
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice